Trametinib Promotes MEK Binding to the RAF-Family Pseudokinase KSR.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2020-138
Abstract: The MEK inhibitor trametinib caused MEK to engage KSR more efficiently than MEK engaged BRAF. read more here.
Keywords: promotes mek; ksr; trametinib; mek binding ... See more keywords